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Abstract
Myc plays an important role in tumor development, including acute myeloid leukemia (AML). However, MYC is also a
powerful inducer of apoptosis, which is one of the major failsafe programs to prevent cancer development. To clarify the
relative importance of the extrinsic (death receptor-mediated) versus the intrinsic (mitochondrial) pathway of apoptosis in
MYC-driven AML, we coexpressed MYC together with anti-apoptotic proteins of relevance for AML; BCL-XL/BCL-2 (inhibiting
the intrinsic pathway) or FLIPL (inhibiting the extrinsic pathway), in hematopoietic stems cells (HSCs). Transplantation of
HSCs expressing MYC into syngeneic recipient mice resulted in development of AML and T-cell lymphomas within 7–9
weeks as expected. Importantly, coexpression of MYC together with BCL-XL/BCL-2 resulted in strongly accelerated kinetics
and favored tumor development towards aggressive AML. In contrast, coexpression of MYC and FLIPL did neither accelerate
tumorigenesis nor change the ratio of AML versus T-cell lymphoma. However, a change in distribution of immature
CD4
+CD8
+ versus mature CD4
+ T-cell lymphoma was observed in MYC/FLIPL mice, possibly as a result of increased survival
of the CD4+ population, but this did not significantly affect the outcome of the disease. In conclusion, our findings provide
direct evidence that BCL-XL and BCL-2 but not FLIPL acts in synergy with MYC to drive AML development.
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Introduction
Acute myeloid leukemia (AML) represents a clonal expansion of
hematopoietic stem and myeloid progenitor cells that have
undergone malignant transformation [1,2]. The leukemic cells
are typically blocked in their differentiation and exhibit an
abnormal extension of life span. Clinically it is a heterogeneous
group of tumors. However, genetic studies during recent years
have highlighted two common types of genetic changes, named
class I and II, in AML [1,2]. Class I comprise point mutations in
genes involved in signal transduction, such as Ras, FLT3 and Kit,
which control cell growth, survival and migration. Class II include
a number of different translocations that all involves transcription
factors such as MLL, AML1, CBF, EVI1 and RARa, which
control the myeloid differentiation program, resulting in fusion
proteins with aberrant activities [1,2]. A common target gene for
the class II translocation products and for deregulated signal
transduction caused by some class I mutations is the oncogene/
transcription factor MYC [3,4]. MYC controls numerous genes
involved in stem cell functions, differentiation, growth, immortal-
ization, metabolism, survival and other fundamental cellular
processes, and deregulated expression of MYC is very often
implicated in human tumor development including hematological
malignancies [5,6]. For instance in Burkitt’s lymphoma, MYC
expression is deregulated through chromosomal translocations
juxtaposing MYC and one of the immunoglobulin loci. Amplifi-
cations of MYC family genes (MYC, MYCN, MYCL) are common in
a number of tumor types and are also found in AML although at a
low frequency [5,6]. Trisomy of chromosome 8 (where MYC
resides) is common in AML, and the resulting increased MYC gene
dosage has been suggested as a leukemogenesis mechanism [7]. In
addition, both MYC and MYCN are frequently overexpressed in
AML as a result of oncogenic events such as the class I and II
mutations mentioned above [8,9,10]. As a consequence, the
tumorigenic effect of the MLL-ENL translocation, one of the most
devastating translocations in AML, was shown to be dependent on
MYC expression [4]. Further evidence linking MYC to AML are
the findings that enforced expression of MYC or MYCN in
hematopoietic stem cells induce AML in mouse models [10,11].
Overexpression of MYC in cells in culture or in animal models
fuels cell growth and proliferation but is also a potent trigger of the
apoptotic machinery, which acts as a failsafe mechanism to
suppress tumorigenesis [5,6]. Both the intrinsic (mitochondrial)
pathway and the extrinsic (death receptor-mediated) pathways of
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expression [12,13]. Firstly, Myc is known to induce p19Arf, which
activates p53, one of the main pathways controlling apoptosis [14].
p53 frequently becomes mutated during progression of MYC-
induced tumors and targeted deletion of p53 accelerates MYC-
induced B-lymphoma development in the Em-myc transgenic
mouse model [15]. Secondly, MYC suppresses the expression of
the anti-apoptotic proteins such as BCL-XL and BCL-2, which
regulate the intrinsic pathway. This mechanism is often bypassed
during lymphoma progression of Em-myc mice [16]. Further,
overexpression of BCL-2 or BCL-XL in these mice [17,18] or in
transplanted bone marrow cells [11,19] accelerates MYC-driven
tumor development, suggesting that BCL-2 and BCL-XL act in
synergy with MYC in tumorigenesis. Moreover, Myc induces
expression of pro-apoptotic proteins such as Bim and Bax [20,21].
Thirdly, MYC sensitizes cells to death receptor-mediated
apoptosis mediated by Fas-ligand, TNF-a or TRAIL [12,13,
22,23]. One reason for this could be that MYC upregulates
expression of the TRAIL receptor DR5 and the Fas-ligand
[5,23,24]. Further, epigenetic silencing of the caspase 8, which is
the downstream effector of the death receptors, has been
implicated in escape from apoptosis in MYCN-amplified neuro-
blastoma [25]. In support of this view, cells lacking Fas or TRAIL-
R show increased survival in the Em-myc lymphoma model [26,27].
Part of the increased response to death receptor signaling could be
accounted for through MYC-induced suppression of NFkB and
activation of Bak, facilitating caspase 8-mediated activation of Bax
[28]. FLIP (CFLAR), another important regulator of death
receptor-mediated apoptosis [29], inhibits apoptosis induced by
death receptors of the TNFR superfamily by binding to caspase 8
at the death-inducing signaling complex (DISC) thereby blocking
its activation [30]. FLIP can act as a tumor progression factor by
promoting tumor establishment and growth in vivo [31,32,33].
Overexpression of MYC in myeloid cell lines has been shown to
cause premature down regulation of FLIPL, thereby triggering the
death receptor pathway [34]. Overexpression of FLIPL in these
cells could completely rescue the cells from apoptosis [34].
Further, MYC was shown to repress FLIPL expression in a
number if cells types both in culture and in vivo by binding to the
FLIPL gene promoter region, resulting in increased sensitivity to
TRAIL-induced apoptosis [35]. Several of these pathways are
important for AML development. The class I mutations described
above synergize with class II translocations at least in part by
suppressing apoptosis, for instance by activating the RAS, MAPK
and PI3 kinase pathways [1]. Overexpression of BCL2, BCL-XL
and/or MCL-1 and reduced expression of Bax is frequently
observed in AML. AML cells are often resistant to TRAIL- and
Fas-induced apoptosis, which has been attributed to death
receptor or FADD downregulation, caspase 8 mutations or
overexpression of FLIPL [36].
Although the contribution of the extrinsic pathway to MYC-
induced apoptosis has been studied extensively in different cell
types in culture, only a few studies of the importance of this
pathway for MYC-driven tumorigenesis in vivo have been
performed (26, 27, 50), all using B- or T-lymphoma models.
The potential impact of this pathway on MYC-induced AML is
therefore unknown. In particular, the relative importance of the
intrinsic and the extrinsic anti-apoptotic pathways in tumorigen-
esis fueled by MYC in vivo, including AML, remains to be
determined.
The aim of this work was to assess the in vivo-impact of these two
apoptotic pathways during MYC-induced malignant transforma-
tion of hematopoietic stem cells. We therefore coexpressed MYC
together with anti-apoptotic gene products of either the extrinsic
death receptor-mediated pathway (FLIPL) or the intrinsic
(mitochondrial) pathway of apoptosis (BCL-2 or BCL-XL)i n
hematopoietic stem cells (HSC) followed by transplantation of the
cells into syngeneic recipient mice. Expression of MYC alone in
HSC resulted in development of both myeloid and T-lymphoid
tumors within two months after transplantation. Expression of
MYC together with BCL-XL or BCL-2 resulted in almost
immediate development of AML-like disease. Surprisingly and
contrary to our expectations, expression of MYC together with
FLIPL did not accelerate tumorigenesis. However, while the ratio
of AML versus T-cell lymphoma was not altered, the incidence of
mature CD4
+ T-cell lymphoma increased at the expense of
immature CD4
+/CD8
+ T-cell lymphoma in MYC/FLIPL mice.
In conclusion, anti-apoptotic proteins of the intrinsic pathway
accelerate the development of MYC-driven hematopoietic tumors
to a larger extent than those of the extrinsic pathway of apoptosis.
Materials and Methods
Cell lines and mice
The human retroviral packaging cell line Phoenix-Eco (kindly
provided by Dr. G. P. Nolan, Stanford University, CA, USA) was
grown as described [37]. Female age-matched (6–8 weeks) inbred
DBA/2 and BALB/c mice were purchased from Taconic (Lille
Skensved, Denmark) or from the animal facility at the Department
of Microbiology, Tumor and Cell Biology, Karolinska Institutet.
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the Swedish Board of Agriculture and
the Department of Microbiology, Tumor and Cell Biology (MTC),
Karolinska Institutet. The protocol was approved by the Ethical
Committee of the Swedish board of Agriculture, North of
Stockholm (Permit Number N99/11). All efforts were made in
order to minimize animal suffering.
Expression vectors
The pMSCV-IRES-EYFP vector was produced by replacing the
enhanced green fluorescent protein (EGFP) of the pMSCV-IRES-
EGFP vector (kindly provided by Dr. A. Nienhuis, St. Jude
Children’s Research Hospital, Memphis, USA) with the enhanced
yellow fluorescent protein (EYFP) of pEYFP (Clontech, Palo Alto,
CA) using the NcoI and NotI sites. The pMSCV-BCL-XL-IRES-
EGFP vector was obtained by subcloning the EcoRI fragment
containing human BCL-XL from the pLXIN-BCL-XL expression
vector [38] into pMSCV-IRES-EGFP. The pMSCV-FLIPL-IRES-
EGFP vector was generated as described previously [39]. MYC was
isolated by PCR from cDNA from muscle cells from the Human
Multiple Tissue cDNA (MTC) Panel 1 (Clontech) using the primers
59-acgtgaattccaccatgcccctcaacgttagcttc and 59-tacgtctcgagcttacgca-
caagagttccgtag and subsequently cloned into the EcoRI and XhoI
sites of pMSCV-IRES-EYFP to obtain the pMSCV-MYC-IRES-
EYFP expression vector. pMSCV-BCL-2-IRES-EGFP was ob-
tained by subcloning human BCL-2 from the cDNA clone
MGC:21366 into the EcoRI site of pMSCV-IRES-EGFP.
Production of retroviral particles
Ten micrograms of the plasmids pMSCV-IRES-EGFP (GFP),
pMSCV-IRES-EYFP (YFP), pMSCV-BCL-XL-IRES-EGFP (BCL-
XL-GFP), pMSCV-BCL-2-IRES-EGFP (BCL-2-GFP), pMSCV-
FLIPL-IRES-EGFP (FLIPL-GFP) or pMSCV-MYC-IRES-EYFP
(MYC-YFP) expression vectors were used to transiently transfect
Phoenix-Eco packaging cell line using Lipofectamine 2000 Reagent
(Invitrogen Ltd, Paisley UK). Supernatants containing recombinant
viral particles were harvested 48 and 72 hours after transfection,
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used for viral transduction.
Hematopoietic stem cell enrichment and retroviral
transduction
Bone marrow was extracted from the femur and tibia of mice
48 h after i.p. injection of 150 mg/kg of 5-fluorouracil (Mayne
Pharma Pic, Warwickshire, UK). Bone marrow cells were
enriched for hematopoietic progenitors and stem cells by negative
selection using the StemSep kit (StemCell Technologies Inc.,
Vancouver, BC, Canada) according to the manufacturer’s
specifications. Cells were cultured for 24 hours in OPTIMEM
(Invitrogen) supplemented with 10% FCS, 2 mM L-glutamine,
1 mM sodium pyruvate, 50 U/ml penicillin, 50 mg/ml strepto-
mycin, IL-6, IL-3 and SCF containing supernatants [40]. The
hematopoietic stem cells were then co-transduced by two rounds
of spin infection with combinations of GFP, YFP, BCL-XL-GFP,
BCL-2-GFP, FLIPL-GFP and MYC-YFP in the presence of 8 mg/
ml polybrene (Sigma, St Louis, MO, USA). This procedure was
repeated for three consecutive days and the cells were then
cultured for another three days. The percentage of GFP and YFP
positive cells were measured by flow cytometry prior to
transplantation. Non-transduced cells were sometimes used to
dilute GFP+/YFP+ cells to frequencies below 5%. Transplanta-
tion was performed by intravenous injection of 1610
6 cells into
lethally irradiated (800rad for BALB/c or 960 rad for DBA/2)
syngeneic recipient mice. The mice were given 8 mg/ml of
doxycycline (Doxyferm; Merckle GmbH, Blaubeuren, Germany)
in the drinking water and kept in filter top cages.
Analysis of mice
Mice were monitored three times a week for signs of disease by
palpation and observation and were judged as terminally ill when
they displayed signs of paralysis in limbs or persistently hunched
posture and slow movements. Mononuclear cell suspensions of
spleen, thymus, liver, bone marrow and lymph nodes were
obtained by passing tissues through nylon mesh cell strainers (BD
Biosciences, Bedford, MA, USA). Tissues (lymph node, spleen,
thymus, liver, kidney, heart, lung, bone) from the mice were fixed
in buffered 4% formaldehyde.
Flow cytometry analysis
Single cell suspensions from spleen, thymus, femoral bone
marrow and liver were incubated with mAbs including anti-CD4-
APC, anti-Gr1-APC, anti-CD19-bio, and anti-CD71-bio (BD
PharMingen San Diego CA, USA). Pacific blue-labeled anti-CD8
(clone 2.43), anti-CD11b (clone M1/70.15) anti-Ter119 and anti-
IgM (clone M41) MAb were prepared in our laboratory according
to standard procedures. Biotinylated samples were then incubated
with streptavidin-APC (BD PharMingen) before being analyzed on
a Cyan ADP flow cytometer (Beckman Coulter, Inc., Fullerton,
CA, USA). EGFP and EYFP were detected using 510/21-nm and
550/30-nm bandpass filters separated by a dichroic 525-nm
mirror. Flow cytometric data were analyzed with FlowJo (Tree
Star, Inc., Ashland, OR, USA).
Results
Transduction of hematopoietic stem cells with
retroviruses expressing MYC alone or together with the
anti-apoptotic genes BCL-XL or FLIPL
To study the effects of anti-apoptotic gene products regulating
the intrinsic and extrinsic apoptosis pathway, respectively, on
MYC-driven transformation of hematopoietic stem cells, murine
lineage-negative (Lin
2) hematopoietic stem cells (HSC) were
enriched from bone marrow and transduced with replication
incompetent retroviral expression vectors, followed by transplan-
tation to lethally irradiated syngeneic recipient mice. Expression of
the gene of interest is in this system driven by the retroviral LTR
promoter that gives expression in all lineages of hematopoietic cells
[37,41]. The gene of interest is followed by an internal ribosomal
entry site (IRES) and GFP or YFP reporter genes, resulting in the
production of a bicistronic mRNA. HSC were transduced with
combinations of two different retroviruses, one carrying MYC-
YFP and the other either BCL-XL (regulating the intrinsic
apoptotic pathway) or FLIPL (regulating the extrinsic pathway)
linked to GFP. As controls the same GFP and YFP vectors lacking
other genes were used. Previously, using vectors expressing GFP or
YFP, we have shown that this results in a near to random
frequency of single and double expressing hematopoietic cells after
transduction and transplantation [37]. This experimental ap-
proach allows for a competitive repopulation strategy, whereby the
effects of overexpression of two genes of interest, either alone or in
combination can be studied in vivo. The expression of YFP and
GFP as determined by flow cytometry after transduction of various
combinations of MYC, BCL-XL, FLIPL or control vector into
Lin
2 bone marrow cells prior to transplantation is shown in
Figure 1. Western blot analysis confirmed that MYC, BCL-XL
and FLIPL were all expressed in cells transduced with the
respective retroviral constructs (Figure S1A).
Inhibition of the intrinsic but not the extrinsic pathway of
apoptosis accelerates MYC-driven tumorigenesis and
shortens survival
Transplantation of Lin- bon marrow cells transduced with
Mock-GFP/MYC-YFP resulted in reconstitution of myeloid,
erythroid and lymphoid cells (Figure S2) but 7–9 weeks after
transplantation, mice suddenly started to display signs of disease.
Early signs of disease were ruffled fur, wasting and slow
movements that rapidly developed into hind limb paralysis within
two days. In some cases, also front leg paralysis was detected, and
these animals showed mediastinal tumors invading the spine.
Necropsy of moribund animals showed splenomegaly, grossly
enlarged livers, non-coagulating blood, spotted lungs and in many
animals also enlarged lymph nodes and thymus. This was in sharp
contrast to mice receiving HSC transduced with Mock-GFP/
Mock-YFP that remained healthy during the whole study period of
6 months (data not shown), despite higher frequencies of retroviral
transduction (Figure 1A). The median survival after transplanta-
tion of Mock-GFP/MYC-YFP recipient mice was 56 days after
transplantation (Figure 2A). This is in good agreement with
previous reports on transplantation of MYC-transduced HSC into
irradiated mice [11,19,42,43].
In order to examine the influence of the intrinsic pathway of
apoptosis during MYC-induced malignant transformation HSC
were transduced with a combination of MYC and BCL-XL
(Figure 1C). BCL-XL/MYC recipient mice rapidly became
moribund and had a median survival of only 17 days (Figure 2A,
B and Table 1). BCL-XL therefore significantly accelerated MYC-
induced tumorigenesis. BCL-XL/MYC mice displayed similar
signs of disease as Mock/MYC mice, namely ruffled fur and slow
movements that developed into hind limb paralysis. Necropsy of
moribund BCL-XL/MYC mice showed that tumors were
disseminated throughout the hematopoietic tissues with extensive
involvement of spleen and bone marrow and tumor infiltration of
the liver. We further tested whether over-expression of FLIPL,a
cellular inhibitor of death receptor-mediated apoptosis, would
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cells. HSC were co-transduced with retroviral expression vectors
containing MYC-YFP and FLIPL-GFP (Figure 1D). Surprisingly,
FLIPL/MYC mice displayed similar signs of disease and with a
similar kineticsas Mock/MYC mice (Figure 2A and 2C). All FLIPL/
MYC mice died or were euthanized due to severe signs of sickness
w i t h i n9w e e k sw i t ha5 8d a y sm e d i a ns u r v i v a lt i m ef o rF L I P L/MYC
to be compared with 56 days for Mock/MYC mice. The difference
in survival time between Mock/MYC mice and FLIPL/MYC was
not statistically significant whereas the difference in survival times
between Mock/MYC and BCL-XL/MYC mice was highly
significant (Table 1). Necropsy of moribund FLIPL/MYC animals
showed similar features as Mock/MYC mice, including splenomeg-
aly, hepatomegaly, non-coagulating blood, spotted lungs and in
many animals also enlarged lymph nodes and thymus.
Spleenweightsof recipientmice(showing no signsof disease) were
recorded at 7, 14, 35 and 49 days after transplantation. Figure 3
shows spleen weights at these time points as well as spleen weights of
all moribund mice. Mock-GFP/Mock-YFP recipient mice did not
show signs of splenomegaly at any time although they had somewhat
larger spleens 14 days after transplantation likely due to intensive
reconstitution after irradiation and transplantation (Figure 3A).
Mock-GFP/MYC-YFP mice only had slightly increased spleen sizes
atearlytime pointsup to 5 weeks aftertransplantation(mean weight:
236 mgcomparedto138 mgforMock-GFP/Mock-YFPrecipients).
However, at later time points (+7 weeks), Mock-GFP/MYC-YFP
recipient mice developed severe splenomegaly (mean weight:
816 mg) (Figure 3B). Co-expression of BCL-XL together with
MYC resulted in accelerated development of severe splenomegaly in
all animals 2 weeks after transplantation with mean values for
moribund animals at 504 mg compared to 180 mg in control
Mock/Mock animals and 260 mg in control Mock/MYC mice at 2
weeks after transplantation (Figure 3A, B and D).
As in Mock/Myc mice, FLIPL/MYC mice appeared to have a
latency period before development of splenomegaly (average
spleen weight at 5 weeks after transplantation, 237 mg for FLIPL/
MYC compared to 236 mg for Mock/MYC and 138 mg for
Mock/Mock recipient mice) (Figure 3). Moribund FLIPL/MYC
Figure 1. Expression of the various combinations of genes in Lin
2 cells prior to transplantation. FACS analysis of expression of YFP and
GFP in HSC prior to transplantation in HSC derived from (A) DBA/2 mice transduced with Mock-GFP and Mock-YFP, (B) DBA/2 mice transduced with
Mock-GFP and MYC-YFP, (C) DBA/2 mice transduced with BCL-XL-GFP and MYC-YFP, (D) DBA/2 mice transduced with FLIPL-GFP and MYC-YFP, (E)
BALB/c mice transduced with BCL-XL-GFP or MYC-YFP and (F) BALB/c mice transduced with BCL-2-GFP and MYC-YFP. The percentage of cells
expressing the genes in each quadrant, gated on PI negative cells, is indicated.
doi:10.1371/journal.pone.0031366.g001
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(average 579 mg), to a similar extent as Mock/MYC mice
(average 816 mg).
To ensure that the FLIPL construct was functionally active, Fas-
sensitive A20 cells were transduced with the FLIPL-GFP construct
and thereafter incubated with or without agonistic anti-Fas mAb
for 20 hours and thereafter analyzed by flow cytometry. Figure
S1B shows that FLIPL efficiently inhibited Fas-induced apoptosis
in this system. This suggested that inhibition of the intrinsic but
not the extrinsic pathway of apoptosis synergized with MYC to
promote tumorigenesis of HSC.
Inhibition of the intrinsic but not the extrinsic pathway of
apoptosis drives MYC-driven tumorigenesis towards
acute myeloid leukemia
We next investigated the spectrum of tumors generated by
expression of MYC alone and by coexpression of MYC together
with BCL-XL or FLIPL, respectively, using flow cytometry. Single
cell suspensions from femoral bone marrow, spleen, thymus, liver
and (in a few individual mice) enlarged lymph nodes of mesenteric
or cervical origin were stained with the myeloid markers anti-
CD11b and anti-Gr1, the T-cell markers anti-CD4 and anti-CD8,
the B-cell markers anti-CD19 and anti-IgM, and the erythroid
markers anti-CD71 and Ter119. Mock/Mock animals all showed
similar staining patterns with normal frequencies of myeloid as
well as lymphoid cells (Table S1a). Each Mock/MYC animal
displayed an individual setup of tumors of both myeloid lineages as
well as tumors of T-cell lineage origins (Figure 4, Table S1b).
Moreover, each Mock/MYC animal typically displayed diverse
tumors in different cellular compartments. Bone marrow often
contained tumors of myeloid origin whereas thymus and lymph
nodes (if enlarged) contained T-cell tumors. Spleen and infiltrating
cells of the liver frequently showed a mixed population of both
myeloid and lymphoid origin with increased numbers in separate
Figure 2. BCL-XL and BCL-2 but not FLIPL accelerate Myc-induced hematopoietic tumorigenesis. Kaplan-Meier survival analysis of mice
transplanted with HSC over-expressing (A) Mock-GFP/MYC-YFP in DBA/2, (B) BCL-XL -GFP/MYC-YFP in DBA/2, (C) FLIPL-GFP/MYC-YFP in DBA/2, (D)
BCL-XL-GFP/MYC-YFP in BALB/c and (E) BCL-2-GFP/MYC-YFP in BALB/c. Mice were monitored daily for tumors or signs of paralysis and killed if
showing signs of sickness. The percentage of mice surviving at daily intervals is shown.
doi:10.1371/journal.pone.0031366.g002
Table 1. Statistical analysis of survival data after transplantation of hematopoietic stem cells expressing MYC, BCL-XL, BCL-2 and/or
FLIPL.
Mock-GFP/MYC-YFP
(DBA/2)
FLIPL-GFP/MYC-YFP
(DBA/2)
BCL-XL-GFP/MYC-YFP
(DBA/2)
BCL-XL-GFP/MYC-YFP
(BALB/c)
FLIPL-GFP/MYC-YFP (DBA/2) NS* p=0.5077 -
BCL-XL-GFP/MYC-YFP (DBA/2) S p,0.0001 S p,0.0001 -
BCL-XL-GFP/MYC-YFP (BALB/c) S p,0.0001 S p,0.0001 NS p=0.2156 -
BCL-2-GFP/MYC-YFP (BALB/c) S p,0.0001 S p,0.0001 S p=0.0004 S P,0.0001
Statistical analysis of the survival data presented in Figure 2.
*Log-rank (Mantel-Cox) test. NS=non significant. S=significant. P-value indicated below.
doi:10.1371/journal.pone.0031366.t001
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+, but also individuals
with increased numbers of CD8
+ and CD4
+CD8
+ cells) and often
myeloid cells (Gr1
+CD11b
+, CD11b
+ and/or Gr1
+). Analyses of
spleen cells from a few representative Mock/MYC mice are shown
in Figure 4. Individual animals could have increased numbers of
both MYC (GFP
2YFP
+) and Mock/MYC (GFP
+YFP
+) cells as
exemplified by MYC/Mock #176 spleen (Figure 4) where the
GFP
+YFP
+ subpopulation was mainly CD11b
+ and the
GFP
2YFP
+ subpopulation could be further divided into a
Gr1
+CD11b
+ and a CD4
+CD8
+ population, indicating that these
tumors were of oligoclonal nature.
In contrast, the vastly dominating cell type among BCL-XL-
GFP/MYC-YFP expressing cells were myeloid CD11b
+Gr1
+ cells,
which accounted for around 50% of the cells in bone marrow and
spleen (Table S1d and Figure 5). Also the livers of moribund mice
were heavily infiltrated with BCL-XL-GFP/MYC-YFP expressing
myeloid CD11b
+Gr1
+ cells (Figure 5). Mice transplanted with
MYC/BCL-XL had a pronounced leukocytosis compared to
Mock/Mock transplanted mice (Figure S3). A differential count of
the blood confirmed that approximately 50% of cells in the MYC/
BCL-XL mice were blasts (Figure S3 and Table S2). These results
indicate that BCL-XL drives MYC-driven tumorigenesis towards
acute myeloid leukemia. These results differ from a report by Luo
et al [11] that suggested that expression of MYC alone in bone
marrow cells transplanted into recipient hosts give rise to AML,
while coexpression of MYC and BCL-2 gave rise to a mixture of
AML and pre-B acute lymphoid leukemia in BALB/c mice (see
Discussion). In order to generalize our finding to other anti-
apoptotic members of the BCL-2 family and also to other strains of
mice, MYC was over expressed together with BCL-XL or BCL-2
in HSC of BALB/c mice followed by transplantation (Figure 1E-
F). Mice transplanted with this combination rapidly developed a
similar AML-like disease as did DBA/2 mice transplanted with
HSC over expressing BCL-XL and MYC. Mean survival time was
16 days for BCL-XL/MYC BALB/c mice (Figure 2D) and 19 days
for BCL-2/MYC BALB/c mice (Figure 2E). This minor difference
in survival time between BCL-XL/MYC and BCL-2/MYC mice
was statistically significant but is most likely a reflection of the
lower proportion of BCL-2/MYC double expressing cells among
the transplanted cells (Table 1, Figure 1). Co-expression of BCL-
XL or BCL-2 together with MYC resulted in splenomegaly in all
animals with mean values for moribund animals at 757 mg for
BCL-XL/MYC BALB/c (Figure 3E) and 899 mg for BCL-2/
MYC BALB/c mice (Figure 3F). All tumors predominantly
expressed the granulocyte markers Gr1 and CD11b and were
GFP
+/YFP
+ (Figure 5, Table S1e-f), thus confirming the results
from the DBA/2 mice. For MYC alone, similar results concerning
the kinetics of tumor development and the frequencies of myeloid
versus lymphoid tumor cells were obtained using BALB/c mice
(data not shown).
As in Mock/MYC mice, FLIPL/MYC mice primarily devel-
oped tumors of myeloid (Gr1
+CD11b
+, CD11b
+ and/or Gr1
+)o r
T-cell lineage origin (CD4
+). FLIPL/MYC spleen and infiltrating
cells of the liver frequently showed a mixed population of both
myeloid and lymphoid origin as in Mock/MYC mice (Table S1b-
c). One notable difference to cells expressing MYC alone was that
the double positive CD4
+CD8
+ lymphoid tumor cells population
was diminished among FLIPL/MYC-expressing cells in favor of
Figure 3. Over-expression of BCL-XL and BCL-2 accelerate Myc-induced splenomegaly whereas co-expression of FLIPL does not
influence MYC-induced splenomegaly. Spleen weight of animals transplanted with HSC expressing (A) Mock-GFP/Mock-YFP into DBA/2 mice, (B)
Mock-GFP/MYC-YFP into DBA/2 mice, (C) FLIPL-GFP/MYC-YFP into DBA/2 mice, (D) BCL-XL-GFP/MYC-YFP into DBA2 mice, (E) BCL-XL-GFP/MYC-YFP
into BALB/c mice and (F) BCL-2-GFP/MYC-YFP into BALB/c. Spleens of mice at control time points (7 days, 14 days, 35 days and 49 days after
transplantation) and spleens of all moribund mice were weighed. Each dot represents one mouse.
doi:10.1371/journal.pone.0031366.g003
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plays a role in the selection of MYC-induced lymphoid but not of
myeloid tumor cells in this system.
Immunohistochemical analyses confirmed and extended the
cytometrical results. Sections of spleen and liver were stained with
Abs against the T-cell markers CD45R and CD3 and the myeloid
marker myeloperoxidase (MPO) (See Materials and Methods S1).
Extensive staining with CD3 and MPO could be observed in
spleen and liver of Mock/MYC recipient mice. In liver, CD3
+ cells
were predominantly distributed as perivascular ‘‘cuffs’’ in contrast
to a more diffuse distribution of myeloid cells. Splenic architecture
was heavily distorted with an expanded red pulp, immunohisto-
chemically dominated by CD3
+ and MPO
+ cells (Figure S4). No
infiltration could be detected in livers of Mock/Mock recipient
mice and spleens showed a normal architecture (Figure S5). In
MYC/BCL-XL or MYC/BCL-2 mice tumor cells in spleen and
liver expressed the myeloid marker MPO but not the T-cell
markers (Figure S6 and S7). Immunohistochemical stainings of
tumor cells in FLIPL/MYC mice showed similar staining patters as
Mock/MYC (Figure S8).
Tumor cell lines could be established from all moribund Mock/
MYC, MYC/BCL-XL, MYC/BCL-2 and MYC/FLIPL recipient
mice. These cells were further characterized by flow cytometry
and all MYC-YFP
+ appeared with similar phenotypes as the
primary tumors (data not shown).
These results are summarized in Figure 6 and suggest that
Mock/MYC mice developed myeloid leukemia and lymphoblastic
T-cell lymphoma. Coexpression of MYC and BCL-XL or BCL-2
strongly favored tumor development towards myeloid leukemia,
whereas coexpression of MYC and FLIPL did not affect the
distribution of myeloid versus lymphoid tumor cells, but changed
the ratio between single CD4
+ and double positive CD4
+CD8
+ T-
cell lymphomas.
Early expansion of myeloid leukemic cells in MYC and
MYC/BCL-XL expressing mice at the expense of other
hematopoietic cell populations
In order to follow leukemia/lymphoma development kinetically
and to gain insight into how different blood cell populations were
affected by MYC and MYC/BCL-XL expression, hematopoietic
development was studied in detail at 7, 14 and 35 days after
transplantation of Mock/MYC- or MYC/BCL-XL-transduced
HSC into recipient mice. Figure S2 (middle columns, top row)
shows that MYC-YFP-expressing cells dominated among cells in
bone marrow and spleen already at day 7. In bone marrow and
spleen, MYC-YFP-expressing cells constituted about 50% of all
cells. This figure was rather constant between 7 and 35 days after
transplantation. At the time of transplantation, only about 6% of
the cells expressed MYC-YFP, indicating that these cells
underwent a rapid expansion to reach high steady-state levels in
vivo. Mock-GFP/Mock-YFP-expressing cells, on the other hand,
did not expand and were kept at constant relative numbers
reflecting the proportions of transduced cells before transplanta-
tion (Figure S2, left columns, top row). BCL-XL-GFP/MYC-YFP
expressing cells in bone marrow expanded from about 20% of the
cells at day 7 to 75% at day 14 after transplantation. In spleen,
BCL-XL-GFP/MYC-YFP expressing cells expanded from 20% at
day 7 to 40% at day 14 (Figure S2, right columns, top row).
Next, the phenotypes of cells expressing Mock-GFP, MYC-YFP
and BCL-XL-GFP/MYC-YFP were analyzed. In figure S2
(middle panels) it can be seen that the dominating cell type
among expanded MYC expressing cells was the myeloid
CD11b
+Gr1
+ cell population, which accounted for around 60%
of the cells in the bone marrow and 20–30% in spleen already at
day 7 and thereafter. Corresponding figure for Mock-expressing
cells was considerably lower. MYC expression was readily
detectable in pre-B, B, CD4
+ and CD8
+ T cells and in erythroid
Ter119
+CD71
hi and Ter119
+CD71
lo cells but did not result in
their expansion. A tendency towards expansion of CD19
+IgM
2
and CD8
+ T cells could be recorded among MYC-expressing cells
in the spleen at day 35. BCL-XL-GFP/MYC-YFP expressing cells
could be found in pre-B, B, CD4
+, CD8
+ T cells and in erythroid
Ter119
+CD71
hi and Ter119
+CD71
lo cells, in particular at day 14
(Figure S2, right panels). However, the vastly dominating cell type
among expanded BCL-XL-GFP/MYC-YFP expressing cells
already at day 7 were myeloid CD11b
+Gr1
+ cells, which
accounted for around 60% of the cells in bone marrow and
spleen at day 14.
Overall, these results indicate that the myeloid CD11b
+Gr1
+
population dominated at early time points both in mice
transplanted with MYC-YFP- and BCL-XL-GFP/MYC-YFP-
expressing HSCs. The expansion of other cell populations lagged
behind and was only evident in MYC-expressing mice at day 35, a
Figure 4. Overexpression of MYC in HSC induces both myeloid and lymphoid leukemia. Flow cytometry analysis of bone marrow and
spleen cells from two individual moribund Mock/MYC mice (indicated with # in the left). In the middle, percentage of GFP
+YFP
+ (Mock/MYC
expressing) cells or GFP
2YFP
+ (MYC expressing) cells are indicated. These cells were further characterized with anti-CD11b, anti-Gr1, anti-CD4, anti-
CD8, anti-CD19, anti-IgM anti-CD71 and anti-Ter119. The percentage of cells in each quadrant is indicated.
doi:10.1371/journal.pone.0031366.g004
Figure 5. Overexpression of BCL-XL-GFP/MYC-YFP induces
AML. Flow cytometry analysis of bone marrow (top), spleen (middle)
and liver (bottom) cells from one representative moribund BCL-XL-GFP/
MYC-YFP mouse. Single cell suspensions from femoral bone marrow,
spleen and liver were stained with anti-CD11b and anti-Gr1. The
percentage of dominating cells is indicated.
doi:10.1371/journal.pone.0031366.g005
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AML.
MYC- and MYC/BCL-XL-expressing CD11b
+Gr1
+, pre-B
and B cells become blast transformed early after
transplantation
To study activation and blast transformation of myeloid and B
lymphoid cells, differences in mean fluorescence intensity (Dmfi) in
forward scatter were analyzed in CD11b
+Gr1
+, CD19
+IgM
2 and
CD19
+IgM
+ cells from bone marrow and spleen 14 days after
transplantation. BCL-XL/MYC and MYC expressing cells of all
these phenotypes were clearly blast transformed compared to non-
transduced cells, cells expressing Mock-GFP or cells expressing
only BCL-XL-GFP within the same animal (Figure 7, A–B middle
and right panels). Similar results were obtained at 7 days and 35
days after transplantation (data not shown). For CD19+IgM+B
cells, increased cell size was noted for MYC/BCL-XL cells
compared to cells expressing MYC only, perhaps indicating
increased survival of such cells in the presence of BCL-XL. It was,
however, mainly MYC- and MYC/BCL-XL-expressing myeloid
CD11b
+Gr-1
+ cells that expanded and rapidly reached elevated
steady-state levels (Figure S2). In summary, mice transplanted with
MYC- or MYC/BCL-XL-expressing cells, contained large num-
ber of pre-malignant MYC-expressing cells of various lineages.
These populations remained at steady-state levels until about 6–7
weeks after transplantation in MYC-expressing mice, when
exponential growth of some of these cell populations suddenly
ensued. At this time point MYC/BCL-XL-expressing mice had
died from AML.
Discussion
Several lines of evidence from the human disease and mouse
models have implicated the MYC oncogene in development of
AML [3,4,8,10,11,19,42,43,44,45,46]. However, deregulated
MYC expression has also been shown to induce the two major
pathways of apoptosis, the intrinsic and the extrinsic (death
receptor) pathways [15,20,23,34,35,47]. This anti-tumorigenic
property of MYC needs to be overcome for tumor development
to occur, and mutations or deregulated expression of components
of both the intrinsic and extrinsic pathways have been
documented in AML [36], although the relative contribution of
these pathways for the disease has not been investigated
systematically. In order to explore the role of these two pathways
of apoptosis during MYC-induced AML, we have overexpressed
MYC in HSC, the tumor-initiating cell of AML, either alone or
together with cellular inhibitors of the intrinsic or the extrinsic
pathways of apoptosis of particular relevance for AML; BCL-XL,
BCL-2 and FLIPL. The transduced HSC were transplanted to
lethally irradiated syngeneic recipient mice after which tumor
development was monitored.
Figure 6. Tumor phenotype in Mock/MYC, FLIPL/MYC, BCL-XL/MYC and BCL-2/MYC recipient mice. Summary of flow cytometry analysis
of spleen cells from moribund mice transplanted with HSC expressing (A) Mock-GFP/MYC-YFP into DBA/2 mice, (B) FLIPL-GFP/MYC-YFP into DBA/2
mice, (C) BCL-XL-GFP/MYC-YFP into DBA2 mice, (D) BCL-XL-GFP/MYC-YFP into BALB/c mice and (E) BCL-2-GFP/MYC-YFP into BALB/c mice. Left panel
specify tumors expressing MYC-YFP only and right panel specify cells expressing MYC-YFP together with either Mock-GFP (A), FLIPL-GFP (B), BCL-XL-
GFP (C and D) or BCL-2-GFP (E). Filled box indicate tumor phenotype. M indicates tumors of myeloid lineage, DP indicate CD4
+CD8
+ lymphoid tumors,
4 indicate CD4
+ lymphoid tumors and 8 indicate CD8
+ lymphoid tumors. Numbers correspond to identity of individual animal.
doi:10.1371/journal.pone.0031366.g006
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pressing MYC developed myeloid leukemia and T cell lymphoma
within 9 weeks, in agreement with previous reports [11,19,42,43].
Importantly, coexpression with BCL-XL or BLC-2 strongly
accelerated MYC-induced tumorigenesis and all mice died or
were moribund within 2 weeks after transplantation. Co-
expression of MYC with BCL-XL or BCL-2 also influenced the
tumor phenotype; Rather than a mixed phenotype of myeloid and
T lymphoid tumors, development of an aggressive AML-like
disease was favored (Figure 6). The synergistic effect of MYC and
Figure 7. Blast formation of Mock-GFP/Mock-YFP, Mock-GFP/MYC-YFP or BCL-XL-GFP/MYC-YFP bone marrow and spleen cells. (A)
Forward light scatter of CD11b
+Gr1
+ bone marrow cells from Mock-GFP/Mock-YFP, Mock-GFP/MYC-YFP and BCL-XL-GFP/MYC-YFP recipient mice 2
weeks after transplantation. Grey thick lines indicate GFP
2YFP
+ cells, thick black lines indicate GFP
+YFP
2 cells and thin lines indicate GFP
+YFP
+ cells.
(B) Difference in mean fluorescence intensity (Dmfi) in forward scatter of CD11b
+Gr1
+ (left), CD19
+IgM
2 (middle) and CD19
+IgM
+ (right) cells in bone
marrow (top) and spleen (bottom) between GFP
2YFP
2 (non-transduced cells) and GFP
2YFP
+ (black bars), GFP
+YFP
+ (striped bars) or GFP
+YFP
2
(white bars) cells are shown. Values indicate means of three individual mice and error bars indicate 1 SD.
doi:10.1371/journal.pone.0031366.g007
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observed here is in agreement with previous observations in
transgenic Em-MYC/BCL-2-induced B lymphoma [17,18]. How-
ever, although using an AML mouse model based on transplan-
tation of transduced bone marrow cells into irradiated recipient
hosts similar to this study, Luo et al. [11] reported that BCL-2 did
not accelerate MYC-induced AML, but rather stimulated
development of pre-B acute lymphoid leukemia (ALL). We could
not reproduce the results of Luo et al in our model using the same
genes and mouse strain (see further discussion below). Our detailed
studies of the kinetics of tumor development showed that
overexpression of MYC, either alone or together with BCL-XL
or BCL-2, rapidly resulted in blast transformation of various
hematopoietic cell types, including myeloid and lymphoid cells.
However, only myeloid cells expanded, and in the case of MYC
expression they rapidly reached a steady-state level that was kept
until about 7–9 weeks after transplantation, when suddenly a fatal
expansion ensued. In the case of MYC and BCL-XL or BCL-2 co-
expression, myeloid cells expanded exponentially already within a
few days after transplantation. Our results indicate that different
hematopoietic cell lineages are differentially permissive for
oncogenic transformation. It is likely that an early expansion of
the MYC-transformed myeloid leukemia cells is counteracted by
MYC-induced apoptosis that is overcome by BCL-XL or BCL-2
expression, resulting in an almost immediate tumor transformation
of myeloid CD11b/Gr1-positive cells, subsequently causing AML.
Our results are in line with a recently published study by Beverly
and Varmus [19] in which MYC was overexpressed together with
each of the 6 known anti-apoptotic members of the BCL-2 family
in bone marrow cells transplanted into irradiated hosts like here,
all resulting in acceleration of MYC-induced AML-like disease.
The reason for the discrepancy in relation to Luo et al. [11] is
unclear, but may be due to differences in the purification of the
retroviral target bone marrow cell population (see further
discussion below).
In contrast to the effects of BCL-XL and BCL-2 overexpression,
FLIPL although functional, did not enhance MYC-driven
tumorigenesis, neither with respect to the kinetics nor the relative
proportion of myeloid leukemia versus T cell lymphoma compared
with MYC alone. This result was unexpected considering previous
reports that Myc sensitizes cells, including hematopoietic cells, to
death receptor-induced apoptosis [12,13,22,23,24,25,27,35,48],
involving at least in part MYC-mediated repression of FLIPL
expression [34,35]. There could be several different explanations
to this result. First, it should be noted that all previous studies on
the relation between MYC and FLIPL has been performed in cell
cultures in vitro, and may be less relevant for tumor development
in vivo. Nevertheless, TRAIL-R deficiency has been shown to
enhance MYC-induced lymphomagenesis in the Em-myc model
[27]. However, recent studies suggest that MYC sensitizes death
receptor signaling mainly by regulating BCL-2-family proteins of
the intrinsic pathway and by suppressing NFkB [28,49], which all
are involved in crosstalk with the extrinsic pathway. Through this
mechanism several pathways of MYC-induced apoptosis would be
blocked by BCL-XL and BCL-2, which may explain their
particular importance in Myc-driven AML as shown here. Still,
even if MYC mainly sensitizes the death receptor pathway via
regulating BCL-2-family proteins and NFkB, we would expect
overexpression of FLIPL to have some impact if the death receptor
pathway is important for suppressing AML development. Another
possible explanation is that the death receptor pathway and its
regulation by FLIPL is important for certain MYC-induced
tumors, such as Em-myc driven B cell lymphoma, but less important
in the case of AML. One difference between MYC and MYC/
FLIPL mice was that the ratio between immature CD4
+/CD8
+
and mature CD4
+ T-cell lymphoma was skewed towards CD4
+
lymphoma. This might indicate that overexpression of FLIPL
favors differentiation of T-cell lymphoma cells or increases the
survival of mature CD4
+ T-cell lymphoma cells, but does not
change the overall tumor burden. Previous studies of Myc-induced
CD4
+/CD8
+ T–cell lymphoma in the CD2-MYC model in a lpr
genetic background showed that deletion of Fas did not accelerate
T-cell lymphoma development, although an increased population
of CD4
+ T-cells was found [50]. Smith et al. [45] reported that
MYC-expressing CD4
+ T cells in the VavP-Myc model was more
prone to apoptosis than the corresponding CD4
+/CD8
+ T-cells,
suggesting that FLIPL might contribute to increased survival of this
population in our model system, although this did not contribute
to increased T-cell lymphoma over AML ratio. Any potential
impact of FLIPL on MYC-induced B lymphomagenesis seems to
be masked in this system by the rapid development of AML and
T-cell lymphoma. This conclusion is not incompatible with FLIPL
being important for Myc-driven development of other types of
tumors, such as B lymphoma (26, 27), under other conditions.
Although MYC was over expressed in cells of all hematopoietic
lineages and resulted in blast transformation, morbidity was
primarily due to development of myeloid and/or T-cell tumors.
T-cell lymphomas were similar both in phenotype (CD4
+ or
CD4
+/CD8
+) and latency (7–10 weeks) to those of VavP-MYC17
mice [51]. VavP-Myc17 transgenic animals with high expression
of MYC in nucleated cells of hematopoietic origin have been
reported to mainly develop T-cell lymphomas [51] whereas
transgenic animals with low expression of c-Myc instead mainly
developed myeloid monocytic tumors and only 7% T-cell
lymphomas [45], suggesting that different expression levels of
MYC may provoke different tumor phenotypes. In our experi-
mental system, we were unable to find a direct correlation between
MYC expression levels and myeloid or lymphoid phenotypes, but
we cannot completely rule out that MYC expression levels may
influence the disease phenotype. Most reports where MYC is
expressed broadly in hematopoietic cell types in mice, it seems to
generate either myeloid leukemia, T lymphoma or a mix of these
two tumor types like here, which may reflect different levels of
MYC depending on expression systems used [11,19,42,43,45,
46,51]. Retroviral expression of MYC in bone marrow cells like
here seems more often to result in predominance of myeloid
leukemia [11,42,43], possibly due to lower levels of MYC than in
the Vav promoter system. Another possibility is that the tumor
initiating MYC target cell(s) differ between the systems. This may
also explain differences in MYC-induced tumor types between
different retroviral transduction systems. For instance, Luo et al.
[11], who observed AML in the absence of T-cell lymphoma, used
unfractionated mononuclear bone marrow cells, whereas we
transduced Lin
2 bone marrow cells. In another transplantation
model, overexpression of MYC resulted in development of
aggressive pre-B cell lymphomas, with low penetrance and after
long latency (.100 days) [21]. Here, fetal liver (E14.5) cells were
used for retroviral transduction. Also other methodological aspects
such as choice of retroviral backbone, the use of single or dual
expression vectors or time of culture in vitro prior to transplan-
tation may influence experimental outcome.
In conclusion, our results suggest that MYC-induced transfor-
mation of HSC accelerates and polarizes hematopoietic tumor
development towards aggressive AML by coexpression of
suppressors of the intrinsic but not the extrinsic pathway of
apoptosis. Since all these players have been implicated in the
development of human AML, these results may potentially be of
relevance for further preclinical and clinical studies of this disease.
BCL-XL but Not FLIP Accelerates MYC-Driven AML
PLoS ONE | www.plosone.org 11 February 2012 | Volume 7 | Issue 2 | e31366Supporting Information
Figure S1 Expression and functionality of retroviral
constructs. A. Analysis of proteins from MYC/BCL-XL tumor
cells and Fas-sensitive A20 cells transduced with MSCV-hFLIPL-
IRES-GFP retroviral particles. B. Fas-sensitive A20 cells were
transduced with MSCV-hFLIPL-IRES-GFP retroviral particles.
Transduced or wt A20 cells were thereafter incubated with or
without agonistic anti-Fas mAb (0.25 mg/ml of Jo2) for 20 hours
and thereafter analyzed by flow cytometry using propidium iodide
(PI) to discriminate between live and dead cells.
(TIF)
Figure S2 Early hematopoietic development of DBA/2
mice reconstituted with Mock-GFP/Mock-YFP, Mock-
GFP/MYC-YFP or BCL-XL-GFP/Myc-YFP expressing
HSCs. Phenotypic analysis of bone marrow (left) and spleen
(right) at 7, 14 and 35 days after transplantation of Mock-GFP/
Mock-YFP, Mock-GFP/MYC-YFP or BCL-XL-GFP/MYC-YFP
expressing HSCs into DBA/2 mice was performed with FACS.
The horizontal axis indicates days after transplantation and the
vertical axis represents percentage of cells expressing the marker
indicated to the left. Black triangles: GFP
+YFP
2 cells, black
squares; GFP
2YFP
+ cells and white circles; GFP
+YFP
+ cells.
(TIF)
Figure S3 Appearance of leukemic blasts in the blood of
MYC/BCL-XL recipient mice. Blood smears stained with
May-Grunewald-Giemsa. Blood smear from a Mock/Mock mouse
shows a normal picture with few leukocytes (A) as compared to the
leukocytosis seen in MYC/BCL-XL mice (B) (primary magnifica-
tion 206). Higher magnification shows a dominance of blast-like
cells with only few maturing granulocytes in MYC/BCL-XL mice
(C and D) (primary magnification 606).
(TIF)
Figure S4 Immunohistochemical staining of sections of
spleen and liver of Mock/MYC mice. The section slides
were stained with antibodies directed against the T-cell markers
CD45R and CD3 and the myeloid marker myeloperoxidase
(MPO) and analyzed by immunohistochemistry as described in
Materials and Methods S1.
(TIF)
Figure S5 Immunohistochemical staining of sections of
spleen of Mock/Mock mice. The analysis was performed as
described in the legend to Figure S4.
(TIF)
Figure S6 Immunohistochemical staining of sections of
spleen and liver of MYC/BCL-XL mice. The analysis was
performed as described in the legend to Figure S4.
(TIF)
Figure S7 Immunohistochemical staining of sections of
spleen and liver of MYC/BCL-2 mice. The analysis was
performed as described in the legend to Figure S4.
(TIF)
Figure S8 Immunohistochemical staining of sections of
spleen, liver and thymus of MYC/FLIPL mice. The
analysis was performed as described in the legend to Figure S4.
(TIF)
Materials and Methods S1 Immunohistochemistry.
(DOCX)
Table S1 Flow cytometric analysis of bone marrow,
thymus, spleen and liver in MYC, BCL-XL,, BCL-2,
FLIPL or control virus recipient mice.
(DOCX)
Table S2 Differential count of nucleated cells in pe-
ripheral blood smears in MYC/BCL-XL and control
mice.
(DOCX)
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